Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic hepatitis C, genotype 1;~* treatment-naive.~Exclusion Criteria:~* liver cirrhosis and other forms of liver disease;~* HIV infection;~* hepatocellular cancer;~* cardiac disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Placebo in combination with standard doses of Pegasys and Copegus.
- Part 1: RO5190591 300mg po (Type: EXPERIMENTAL): RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
- Part 1: RO5190591 600mg po (Type: EXPERIMENTAL): RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
- Part 1: RO5190591 900mg po (Type: EXPERIMENTAL): RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
- Part 2: RO5190591 300mg po (Type: EXPERIMENTAL): If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.

Based on this trial design, predict the completion outcome and termination type (if applicable).